Navigation Links
VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives

SOUTH SAN FRANCISCO, Calif., Sept. 13 /PRNewswire-FirstCall/ -- VaxGen Inc. (Pink Sheets: VXGN) today announced further cost-cutting measures consistent with its continuing commitment to align its cost structure with its pursuit of strategic initiatives.


VaxGen is reducing its workforce from 61 to 27 employees, which the company expects will lower its monthly cash expenditures used in operating activities to $1.4 million. The company will incur a restructuring charge of approximately $1.1 million in connection with this action. The terminations include executive officer Lance Ignon, Vice President of Corporate Affairs.

This is VaxGen's third restructuring since the U.S. Department of Health and Human Services (HHS) cancelled the company's contract to provide a modern anthrax vaccine for civilian biodefense in December 2006.

"Throughout this year we have retained only those resources that management felt could build value for our shareholders, either because they enhanced our ability to complete a strategic transaction or they were required to meet essential business objectives," said James P. Panek, VaxGen's President and CEO. "Based on our understanding of the nature and structure of such potential transactions, we are now able to take this further restructuring action. We remain optimistic about completing a strategic transaction and are in various stages of discussions with a variety of companies."

VaxGen has retained key resources necessary to support its pursuit of strategic transactions, including key scientific personnel for technical due diligence. The company has also retained people associated with the company's financial reporting obligations to the Securities and Exchange Commission. "These are not easy decisions, especially when you are talking about letting go of many talented and dedicated employees," Mr. Panek said. "In particular, Lance Ignon has tirelessly and competently fulfilled a variety of responsibilities during his more than seven years of service to VaxGen. Nonetheless, these staffing decisions are appropriate given the opportunities we are pursuing and the obligation we have to our shareholders."

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. For more information, please visit the company's web site at

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the company's ability to reduce monthly cash expenditures used in operating activities and the possibility of selling or merging the company's remaining assets. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

SOURCE VaxGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage
2. OpGen recruits CEO to further gene-mapping business
3. Better collaboration urged to further Wisconsin biotech
4. Johnson Controls jumping further into hybrid-vehicle battery world
5. Preserve Samples for RNA Expression Microarrays RNAlater Around the World
6. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
7. Genomic DNA Preparation from RNAlater Preserved Tissues
8. QBIs PreserveX product passes initial test
9. Technology and mergers: Getting the strategic applications
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... talks at SPIE Photonics Europe 2016, the premier research conference in Europe ... event will run 4-7 April 2016 in the Square Brussels Meeting Centre. ...
(Date:12/1/2015)... Vancouver , booth ... features Owen Mumford,s unique Comfort Zone Technology®. --> ... is a touch activated lancet that features Owen Mumford,s ... a leading medical device manufacturer, today unveils a new ... in the US before expanding out to other markets. ...
(Date:12/1/2015)... , Dec. 1, 2015 Today the Allen ... Seattle,s South Lake Union neighborhood, ... of Mercer Street and Westlake Avenue North, the 270,000 ... Allen Institute for Brain Science and the Allen Institute ... philanthropist and founder of the Allen Institute. "We started ...
(Date:12/1/2015)... Mass. , Dec. 1, 2015 Researchers ... the McGovern Institute for Brain Research at MIT have ... that significantly cut down on "off-target" editing errors. The ... in the use of genome editing. Science ... that changing three of the approximately 1,400 amino acids ...
Breaking Biology Technology:
(Date:12/1/2015)... SAN JOSE, Calif. , Dec. 1, 2015 /PRNewswire/ ... developer of human interface solutions, today announced a new ... to enable OEMs with real-world test and development environments ... Nok Labs solutions. The partnership reduces the complexity of ... servers and software permits Synaptics and OEMs to verify ...
(Date:11/30/2015)... 2015  BIOCLAIM announced today that is has ... Innovation Awards:  Healthcare Edition, an awards program from ... FierceHealthcare , and FierceMobileHealthcare ... the category of "Privacy and Cybersecurity." ... --> Photo - ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Capacitive Fingerprint Sensors - Technology and ... --> --> ... market, especially in smartphones. The fingerprint sensor vendor Idex ... fingerprint sensor units in mobile devices and of the ...
Breaking Biology News(10 mins):